|1.||Vezzani, Annamaria: 3 articles (04/2011 - 07/2006)|
|2.||Ravizza, Teresa: 3 articles (04/2011 - 07/2006)|
|3.||Randle, John C R: 3 articles (05/2007 - 08/2005)|
|4.||Balosso, Silvia: 2 articles (04/2011 - 07/2006)|
|5.||Noé, Francesco: 2 articles (09/2008 - 07/2006)|
|6.||Ku, George: 2 articles (05/2007 - 07/2006)|
|7.||French, Jacqueline: 1 article (04/2011)|
|8.||Maroso, Mattia: 1 article (04/2011)|
|9.||Iori, Valentina: 1 article (04/2011)|
|10.||Wright, Christopher Ian: 1 article (04/2011)|
05/01/2007 - "In addition, VX-765 reduced disease severity and the expression of inflammatory mediators in models of rheumatoid arthritis and skin inflammation. "
01/01/2007 - "We discuss the use of inflammatory caspase inhibitors, such as VX-740 (Pralnacasan) and VX-765, in clinical studies for rheumatoid arthritis and osteoarthritis. "
04/01/2011 - "The same dose regimen of VX-765 also reduced acute seizures in mice and delayed their onset time. "
09/01/2008 - "VX-765 did not affect seizures or afterdischarge duration in fully kindled rats. "
07/01/2006 - "Administration of pralnacasan (intracerebroventricular, 50 microg) or VX-765 (intraperitoneal, 25-200 mg/kg) to rats blocked seizure-induced production of IL-1beta in the hippocampus, and resulted in a twofold delay in seizure onset and 50% reduction in seizure duration. "
04/01/2011 - "Moreover, the effects of this drug were studied in one acute model of seizures in mice, previously shown to involve activation of ICE/caspase-1. Quantitative analysis of electroencephalogram activity was done in mice exposed to acute seizures or those developing chronic epileptic activity after status epilepticus to assess the anticonvulsant effects of systemic administration of VX-765. "
|5.||Cryopyrin-Associated Periodic Syndromes
|1.||Caspase 1 (ICE Protease)
|4.||Anticonvulsants (Antiepileptic Drugs)